ORİJİNAL ARAŞTIRMALAR
Zayıf ve Aşırı Kilolu Polikistik Over Sendromlu Kadınlarda Serum Adipsin Düzeylerinin Değerlendirilmesi
Serum Adipsin Levels of Lean and Overweight Women with Polycystic Ovary Syndrome
Received Date : 06 Nov 2023
Accepted Date : 13 Jun 2024
Available Online : 04 Jul 2024
Fatma TANILIR ÇAĞIRANa, Zercan KALIb
aPrivate Physician, Diyarbakır, Türkiye
bGözde Akademi Hospital, Clinic of Gynaecology and Obstetrics, Malatya, Türkiye
Doi: 10.24074/tjrms.2023-100135 - Makale Dili: EN
Turkish Journal of Reproductive Medicine and Surgery. 2024;8(2):42-7.
ÖZET
Amaç: Obez ve düşük kilolu polikistik over sendromu hastalarında serum adipsin konsantrasyonlarını karşılaştırmak. Gereç ve Yöntemler: 28'i
PKOS ve 28 sağlıklı kontrol olmak üzere toplam 56 hasta çalışmaya dahil edildi. PKOS grubu BMI değerlerine göre iki gruba ayrıldı. BMI 18,5-
24,9 kg/m2 olan 14 hasta normal kilolu PKOS grubunu oluştururken, BMI 25-29,9 kg/m2 olan 14 hasta fazla kilolu kabul edildi. Her iki grubun
plazma adipsin konsantrasyonu ELISA yöntemiyle ölçüldü. Bulgular: Serum adipsin düzeyleri obez PKOS grubunda zayıf PKOS ve kontrollere
göre anlamlı derecede düşük idi. Kontrol grubun serum adipsin düzeyleri hem zayıf PKOS hem de obez PKOS gruplarına kıyasla anlamlı
artış gösterdi. Zayıf PKOS grubu, obez gruba kıyasla daha yüksek adipsin seviyeleri sergiledi. Her iki PKOS grubunda BMI ile adipsin arasında
negatif anlamlı ilişki vardı. BMI'daki artış adipsin düzeyinde azalmaya yol açtı. PKOS gruplarının serum adipsin düzeyleri ile HOMA-IR, LH
ve testosteron arasında negatif ve anlamlı bir korelasyon saptandı. Sonuç: Obezite, PKOS hastalarında adipoz dokunun adipsinin sentez ve salınımını
bozar.
Anahtar Kelimeler: PKOS; Adipozite; Adipsin; HOMA-IR; BMI
ABSTRACT
Objective: To compare serum adipsin concentrations in underweight and overweight polycystic ovary syndrome. Materials and Methods: A
total of 56 patients, 28 of whom were diagnosed with PCOS and 28 were healthy controls were included. PCOS patients were divided into two
groups according to BMI values. While 14 patients with a BMI of 18.5-24.9 kg/m2 constituted the normal weight PCOS group, 14 patients with
a BMI of 25-29.9 kg/m2 were considered overweight PCOS. No hyperandrogenemia, LH, FSH imbalance and PCO morphology were found in
the control group. Serum adipsin concentration of both groups was measured by ELISA method. Results: Serum adipsin levels were significantly
decreased in the obese PCOS group compared to lean PCOS and controls. The serum adipsin levels of the non-PCOS group showed a significant
increase compared to both the lean PCOS and the obese PCOS groups. The lean PCOS group exhibited high adipsin levels compared to the obese
group. There was a negative significant relationship between BMI and adipsin in both PCOS groups. The increase in BMI led to a decrease in
adipsin level. A negative significant correlation was recorded between serum adipsin levels, HOMA-IR, LH and testosterone in PCOS group. Conclusions:
Obesity impairs both synthesis and release of adipsin from adipose tissue of PCOS patients.
Keywords: PCOS, Adiposity; Adipsin; HOMA-IR; BMI
REFERANSLAR
- Gursoy Calan O, Calan M, Yesil Senses P, Unal Kocabas G, Ozden E, Sari KR, et al. Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2016;85(6):910-7. [Crossref] [PubMed]
- Daan NM, Koster MP, de Wilde MA, Dalmeijer GW, Evelein AM, Fauser BC, det al. Biomarker Profiles in Women with PCOS and PCOS Offspring; A Pilot Study. PLoS One. 2016;11(11):e0165033. [Crossref] [PubMed] [PMC]
- Celik N, Aydin S, Ugur K, Yardim M, Acet M, Yavuzkir S, et al. Patatin-like phospholipase domain containing 3-gene (adiponutrin), preptin, kisspeptin and amylin regulates oocyte developmental capacity in PCOS. Cell Mol Biol (Noisy-le-grand). 2018;64(15):7-12. [Crossref] [PubMed]
- Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, Moede T, et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell Mol Biol (Noisy- le-grand). 2014;158(1):41-53. [Crossref] [PubMed] [PMC]
- Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and meta- bolic disease. Nat Rev Immunol. 2011;11(2):85-97. [Crossref] [PubMed] [PMC]
- Karajibani M, Montazerifar F, Sadeghi MB, Keikhaie MA, Dashipour A. Serum fetuin-A and adipsin levels in type II diabetes patients. Int J High Risk Behav Addict. 2019;8(3):e91963. [Crossref]
- Pyrzak B, Ruminska M, Popko K, Demkow U. Adiponectin as a biomarker of the metabolic syndrome in children and adolescents. Eur J Med Res. 2010;15 Suppl 2:147-51. [Crossref] [PubMed] [PMC]
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetolo- gia. 1985;28(7):412-9. [Crossref] [PubMed]
- Mamdouh M, Shaban S, Ibrahim AA, Zaki MMM, Ahmed OM, Abdel-Daim MM. Adipokines: potential therapeutic targets for vascular dysfunction in type II diabetes mellitus and obesity. J Diabetes Res. 2017;2017:1-11. [Crossref] [PubMed] [PMC]
- Blüher M. Adipokines-removing road blocks to obesity and diabetes therapy. Mol Metab. 2014;3(3):230-40. [Crossref] [PubMed] [PMC]
- Cook KS, Groves DL, Min HY, Spiegelman BM. A developmentally regulated mRNA from 3T3 adipocytes encodes a novel serine protease homologue. Proc Natl Acad Sci. 1985;82(19):6480-4. [Crossref] [PubMed] [PMC]
